Splenic marginal zone lymphoma medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 11: Line 11:
===Immunotherapy===
===Immunotherapy===
* In the pre-rituximab era splenectomy was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but ritximab is reported to be more beneficial in old age patients with co-morbid conditions.<ref name="pmid16700034">{{cite journal |vauthors=Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ |title=Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone |journal=Cancer |volume=107 |issue=1 |pages=125–35 |date=July 2006 |pmid=16700034 |doi=10.1002/cncr.21931 |url=}}</ref>
* In the pre-rituximab era splenectomy was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but ritximab is reported to be more beneficial in old age patients with co-morbid conditions.<ref name="pmid16700034">{{cite journal |vauthors=Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ |title=Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone |journal=Cancer |volume=107 |issue=1 |pages=125–35 |date=July 2006 |pmid=16700034 |doi=10.1002/cncr.21931 |url=}}</ref>
* Rituximab was reported to be a better option than splenectomy in terms of complete remission and overall survival of the patient.<ref name="pmid20350661">{{cite journal |vauthors=Bennett M, Schechter GP |title=Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab |journal=Semin. Hematol. |volume=47 |issue=2 |pages=143–7 |date=April 2010 |pmid=20350661 |doi=10.1053/j.seminhematol.2010.01.004 |url=}}</ref>
* Rituximab was reported to be a better option than splenectomy in terms of complete remission and overall survival of the patient.<ref name="pmid20350661">{{cite journal |vauthors=Bennett M, Schechter GP |title=Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab |journal=Semin. Hematol. |volume=47 |issue=2 |pages=143–7 |date=April 2010 |pmid=20350661 |doi=10.1053/j.seminhematol.2010.01.004 |url=}}</ref><ref name="pmid23345547">{{cite journal |vauthors=Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP |title=Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy |journal=Oncologist |volume=18 |issue=2 |pages=190–7 |date=2013 |pmid=23345547 |pmc=3579603 |doi=10.1634/theoncologist.2012-0251 |url=}}</ref>
 
===Chemotherapy===
===Chemotherapy===
===Immunochemotherapy===
===Immunochemotherapy===

Revision as of 17:01, 31 December 2018

Splenic marginal zone lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Splenic marginal zone lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Biopsy

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Splenic marginal zone lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Splenic marginal zone lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Splenic marginal zone lymphoma medical therapy

CDC on Splenic marginal zone lymphoma medical therapy

Splenic marginal zone lymphoma medical therapy in the news

Blogs on Splenic marginal zone lymphoma medical therapy

Directions to Hospitals Treating Splenic marginal zone lymphoma

Risk calculators and risk factors for Splenic marginal zone lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

The predominant therapy for splenic marginal zone lymphoma is surgery. Adjunctive radiotherapy, chemotherapy, and biological therapy may be required. The optimal therapy for splenic marginal zone lymphoma depends on the clinical presentation.

Medical Therapy

  • The optimal therapy for splenic marginal zone lymphoma depends on the clinical presentation.
  • Treatment options for the condition are as under

Watchful waiting

  • It is a slow growing tumor so patients may not need treatment right away unless symptomatic. Asymptomatic patients may be observed every 3-6 months.[1]

Immunotherapy

  • In the pre-rituximab era splenectomy was considered to be the treatment of choice for splenic marginal zone lymphoma and still is performed for its treatment but ritximab is reported to be more beneficial in old age patients with co-morbid conditions.[2]
  • Rituximab was reported to be a better option than splenectomy in terms of complete remission and overall survival of the patient.[3][4]

Chemotherapy

Immunochemotherapy

Treatment of splenic marginal zone lymphoma[5]
Therapy Description
Watchful waiting People may not need treatment right away unless they have symptoms
Splenectomy Often respond very well when their spleen is removed with surgery
Radiation Therapy When a splenectomy is not an option, external beam radiation therapy to the spleen
Chemotherapy Doesn’t respond well to chemotherapy
Biological therapy Rituximab may be used alone or in combination with chemotherapy

References

  1. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, Felman P, Franco V, Iannitto E, Mollejo M, Papadaki T, Remstein ED, Salar A, Solé F, Stamatopoulos K, Thieblemont C, Traverse-Glehen A, Wotherspoon A, Coiffier B, Piris MA (March 2008). "Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria". Leukemia. 22 (3): 487–95. doi:10.1038/sj.leu.2405068. PMID 18094718.
  2. Tsimberidou AM, Catovsky D, Schlette E, O'Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ (July 2006). "Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone". Cancer. 107 (1): 125–35. doi:10.1002/cncr.21931. PMID 16700034.
  3. Bennett M, Schechter GP (April 2010). "Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab". Semin. Hematol. 47 (2): 143–7. doi:10.1053/j.seminhematol.2010.01.004. PMID 20350661.
  4. Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, Kokoris SI, Dimitriadou EM, Dimopoulou MN, Moschogiannis M, Korkolopoulou P, Kyrtsonis MC, Siakantaris MP, Papadaki T, Tsaftaridis P, Plata E, Papadaki HE, Vassilakopoulos TP (2013). "Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy". Oncologist. 18 (2): 190–7. doi:10.1634/theoncologist.2012-0251. PMC 3579603. PMID 23345547.
  5. Splenic marginal zone lymphoma. Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/non-hodgkin-lymphoma/non-hodgkin-lymphoma/types-of-nhl/splenic-marginal-zone-lymphoma/?region=on Accessed on December 23,2015

Template:WH Template:WS